NCT05525702 VR Interventions to Reduce the Prevalence of Delirium in ICU Patients
| NCT ID | NCT05525702 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Delirium |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2023-12-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2023-12-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn the effect of Virtual Reality Family Support System (VRFS) on reducing delirium in ICU mechanically ventilated patients. The main question it aims to answer is: ·Using VRFS for participant intervention, can it reduce the incidence of delirium and improve clinical outcomes? Researchers will investigate whether the implementation of VRFS can reduce the number of delirium days and improve clinical outcomes. Participants will: * Receive the VRFS intervention until the endotracheal tube (ETT) is removed. * Have physiological data collected, including EEG, oxygen saturation levels, ECG, and blood pressure. * Keep a diary of delirium, dosage of sedative and analgesic drugs, the duration of mechanical ventilation, and ICU stays.
Eligibility Criteria
Inclusion Criteria * Mechanical ventilation duration is expected to be greater than 24 hours; * ICU stay duration is expected to be greater than 72 hours; * Age is 18 years or older, with no upper age limit; * Language: Chinese. Exclusion Criteria * Severe visual or auditory impairments (diplopia, low vision due to macular degeneration, retinopathy; severe hearing loss or deafness); * Cognitive and consciousness disturbances prior to ICU admission; * Severe motion sickness; * Head trauma or surgery that prevents the wearing of equipment; * A history of long-term use of antipsychotic and/or benzodiazepine medications.
Contact & Investigator
Yun Long, MD
STUDY DIRECTOR
Peking Union Medical College
Frequently Asked Questions
Who can join the NCT05525702 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05525702 currently recruiting?
Yes, NCT05525702 is actively recruiting participants. Contact the research team at yangyingying2703@outlook.com for enrollment information.
Where is the NCT05525702 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05525702 clinical trial?
NCT05525702 is sponsored by Peking Union Medical College Hospital. The principal investigator is Yun Long, MD at Peking Union Medical College. The trial plans to enroll 102 participants.